Individualizing treatment decisions for older adults with hematologic malignancies.

Published

Journal Article (Review)

Hematologic malignancies are a common cause of morbidity and mortality among older adults, who represent the majority of patients diagnosed with these diseases. Treatment options and disease outcomes have improved in recent years because of the development of novel treatment strategies and the design of elderly-specific clinical trials. Despite this, extrapolation of clinical trial data to patients routinely seen in practice is challenging because of the presence of multimorbidity and functional impairments. Individualized treatment decision making requires not only an understanding of underlying tumor biology but also careful estimation of an older patient's anticipated ability to withstand the stresses of therapy. This article will discuss approaches to standardizing patient assessment strategies and tailoring therapeutic decisions for older adults with hematologic malignancies with a focus on acute myeloid leukemia (AML), allogeneic bone marrow transplantation, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL).

Full Text

Duke Authors

Cited Authors

  • Klepin, HD; Rizzieri, D; Palumbo, A; Magarotto, V; Eichhorst, B

Published Date

  • January 2013

Published In

Start / End Page

  • 208 - 219

PubMed ID

  • 23714504

Pubmed Central ID

  • 23714504

Electronic International Standard Serial Number (EISSN)

  • 1548-8756

International Standard Serial Number (ISSN)

  • 1548-8748

Digital Object Identifier (DOI)

  • 10.1200/edbook_am.2013.33.208

Language

  • eng